E
Enveric Biosciences, Inc. (ENVB)
NCM – Real Time Price. Currency in USD
1.42
+0.14 (10.55%)
At close: Jun 26, 2026, 4:00 PM EDT
1.42
+0.00 (0.33%)
After-hours: Jun 26, 2026, 7:32 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.42
+0.14 (10.55%)
At close: Jun 26, 2026, 4:00 PM EDT
1.42
+0.00 (0.33%)
After-hours: Jun 26, 2026, 7:32 PM EDT
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Dr. Joseph Edward Tucker Ph.D. | CEO & Director |
| Dr. Peter J. Facchini Ph.D. | Chief Innovation Officer |
| Mr. Kevin M. Coveney CPA | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-09 | 8-K | form8-k.htm |
| 2026-06-01 | S-8 | forms-8.htm |
| 2026-05-29 | 8-K | form8-k.htm |
| 2026-05-15 | 8-K | form8-k.htm |
| 2026-05-15 | 10-Q | form10-q.htm |
| 2026-05-04 | D | |
| 2026-04-30 | 8-K | form8-k.htm |
| 2026-04-28 | CORRESP | filename1.htm |
| 2026-04-23 | S-3 | forms-3.htm |
| 2026-04-20 | 8-K | form8-k.htm |